Patients who have had systemic (chemotherapy, biologic therapy or radiotherapy) within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the studyXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy, targeted small molecule therapy, or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\r\n* Note: patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatients must have discontinued chemotherapy, immunotherapy or other investigational agents used in the adjuvant setting >= 4 weeks prior to entering the study and recovered from adverse events due to those agents; mitomycin and nitrosoureas must have been discontinued at least 6 weeks prior to entering the study; patients must have discontinued radiation therapy >= 2 weeks prior to entering the study and recovered from any adverse events associated with treatment; prior surgery must be >= 4 weeks from registration and patients must be fully recovered from post-surgical complicationsXx_NEWLINE_xXPrior Therapy:\r\n* Patients must have had no prior anthracycline (e.g., doxorubicin, daunorubicin) or ifosfamide chemotherapy\r\n* Patients must have had no prior use of pazopanib or similar multi-targeted tyrosine kinase inhibitors (TKI)\r\n* Patients must have had no prior radiotherapy to tumor-involved sites\r\n* Note: patients previously treated for a non-NRSTS cancer are eligible provided they meet the prior therapy requirements; patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier are excludedXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier are excluded; however, the following therapies are allowed: \r\n* Hormone-replacement therapy or oral contraception\r\n* Herbal therapy > 7 days prior to randomization (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to randomization)\r\n* Palliative radiotherapy for bone metastases > 14 days prior to randomizationXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy, hormonal therapy, or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had pelvic radiotherapy prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C), immunotherapy within 3 weeks, targeted therapies (e.g. small molecule inhibitors such as pazopanib) within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; not clinically significant or clinically stable adverse events from prior therapy (e.g. immunotherapy related hypothyroidism or insulin-dependent diabetes stable on medication or tyrosine kinase inhibitor [TKI]-related hypertension or rash etc.) is allowedXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from acute effects of any prior therapy to baseline or grade =< 1 except for alopecia or adverse events (AEs) not constituting a safety risk in the opinion of the investigatorXx_NEWLINE_xXParticipants who have had chemotherapy, immunotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have >= grade 2 adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or immunotherapy within 4 weeks or radiation therapy within 2 weeks prior to start of study treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior treatments:\r\n* Patients who have had systemic cytotoxic therapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or targeted therapy with small molecule inhibitors within 2 weeks prior to entering the study\r\n* Patients who have not recovered from adverse events (=< grade 1; except alopecia) due to agents administered more than 4 weeks earlier\r\n* Patients need to be free of adverse effects (=< grade 1; except alopecia) from prior treatments for at least 14 days from cycle 1 day 1 of PLX3397 and sirolimusXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) before entering the study or those who have not recovered from AEs to ? Grade 1 (except for peripheral neuropathy; see Exclusion Criterion 12) due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXPatients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the studyXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or targeted therapies within 2 weeks prior to entering the study or those who have not recovered (=< grade 1) from adverse events due to agents administered with the exception of any grade of alopeciaXx_NEWLINE_xXParticipants who have had any of the following:\r\n* Chemotherapy in the previous 2 weeks (6 weeks for nitrosoureas or mitomycin C)\r\n* Radiotherapy within 3 weeks\r\n* Investigational agents within 3 weeks prior to entering the study\r\n* Patients who have not recovered from significant (in the opinion of the investigator) adverse events due to previous agents administeredXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXSubjects who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study (e.g. start of study treatment), or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients with incomplete recovery from adverse events due to agents administered more than 4 weeks prior to registration are not eligibleXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C), small molecule targeted therapy (i.e. – kinase inhibitors) within 3 weeks or the last dose of antibody therapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXSubject who has had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than 2 weeks earlier; however, the following therapies are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)Xx_NEWLINE_xXParticipants who have had chemotherapy, targeted small molecule therapy, or radiotherapy within 2 weeks prior to study day 1 (6 weeks for nitrosoureas or mitomycin C) or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to previously administered agents; Note: subjects with =< grade 2 peripheral neuropathy are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXParticipants who have had chemotherapy, biologic therapy, investigational agents, radiotherapy, or major surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the studyXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXChemotherapy or radiotherapy within 1 week (4 weeks for nitroureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy within 2 weeks or 5 half-lives (whichever is longer) from the last dose of chemotherapy prior to the first dose of treatment on the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier; hydroxyurea is allowed per treating investigatorXx_NEWLINE_xXParticipants who have had chemotherapy, radiotherapy, biologic therapy, major surgery, or another investigational agent within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the studyXx_NEWLINE_xXThose who have had chemotherapy or radiotherapy or targeted agents within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients must have recovered to grade 1 or baseline from adverse events (AEs) and/or toxicity of prior chemotherapy or biologic therapy; they must not have had chemotherapy, biologic therapy, or definitive radiotherapy within 4 weeks (6 weeks for nitrosoureas and mitomycin C) or 5 half-lives, whichever is shorter, prior to entering the study; palliative-intent radiotherapy (30 Gy or less) must be completed at least 2 weeks prior to start of treatment, and may not be to a lesion that is included as measurable disease; patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (where a sub-therapeutic dose of drug is administered) at the principal investigator's (PI’s) discretion, and should have recovered to grade 1 or baseline from any toxicitiesXx_NEWLINE_xXHas had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks prior to the first dose of study drug, or has not recovered to Baseline or CTCAE grade 1 from the adverse events due to cancer therapeutics administered >4 weeks earlier.Xx_NEWLINE_xXPatients who have had chemotherapy or other systemic therapy or radiotherapy or patients who have not recovered from adverse events due to prior administered agents as follows:\r\n* Chemotherapy < 4 weeks prior to entering the study\r\n* Radiotherapy < 4 weeks prior to entering the study\r\n* Nitrosoureas/mitomycin C < 6 weeks prior to entering the study\r\n* Targeted therapy < 2 weeks (or 5 half-lives, whichever is longer) prior to entering the study\r\n* Those who have not recovered from clinically significant adverse events due to prior agents administered to grade =< 1 or baseline, with exception of alopecia and peripheral neuropathy, unless approved by the protocol chairXx_NEWLINE_xXPatients who have had chemotherapy within 4 weeks or five half-lives, whichever is shorter, (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; steroids for symptom palliation are allowed, but must be either discontinued or on stable doses at the time of initiation of protocol therapyXx_NEWLINE_xXUse of any other experimental drug or therapy within 21 days of baseline - patients who have had chemotherapy or radiotherapy within 4 weeks of entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy, immune therapy, other investigational therapy, major surgery, or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the studyXx_NEWLINE_xXParticipants who have not recovered to eligibility levels from adverse events due to agents administered prior to study entryXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have received chemotherapy or radiotherapy within 4 weeks prior to entering the study or has not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy, targeted therapies, radiotherapy, or used an investigational device within 2 weeks prior to the first dose of treatment or those who have not recovered from adverse events (i.e., =< grade 1 or at baseline) due to agents administered more than 2 weeks earlier; note: participants with =< grade 2 neuropathy are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXThe patient has not recovered to grade ? 1 from adverse events (AEs) due to investigational drugs or other medications, which were administered more than 4 weeks prior to the first dose of study drug.Xx_NEWLINE_xXPatients who have had chemotherapy within 14 days before entering the study or those who have not recovered from AEs to ? Grade 1 due to agents administered more than 14 days earlier.Xx_NEWLINE_xXPrior chemotherapy or radiation within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks of study drug treatment or those who have not recovered from adverse events due to agents administeredXx_NEWLINE_xXPatients who have had molecular targeted therapy (including vemurafenib) or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXPatients who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXExposure to chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXUse of any other chemotherapy, radiotherapy, or experimental drug or therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to enrollment on study or those who have not recovered from adverse events >= grade 1 due to agents administered more than 4 weeks earlier except for stable grade 2 neuropathyXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the studyXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks (4 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 3 weeks prior to entering the study or those who have not recovered from clinically significant adverse events due to agents administered more than 3 weeks earlier; the Principal Investigator or treating investigator determine if any abnormal laboratory values or toxicities are due to prior agents administered vs. disease and if they are clinically significantXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have chemotherapy, radiotherapy or oral antifungal agents (ketoconazole, itraconazole, fluconazole) within 3 weeks prior to entering the study or those who have not recovered (e.g. back to baseline or grade 1) from adverse events due to agents administered more than 3 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy, immunotherapy, radiotherapy, or investigational therapy within 28 days prior to entering the study or those who have not recovered from adverse events due to agents administered more than 28 days earlier; steroids for control of disease related symptoms are permittedXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier; corticosteroid treatment is allowedXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy =< 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; treatment with glucocorticoids, hydroxyurea, and tyrosine kinase inhibitors is allowed up to 24 hour prior to initiation of therapyXx_NEWLINE_xXPatients who have had chemotherapy, biological therapy or definitive radiation within 4 weeks of the study enrollment or those who have not recovered from adverse events to =< grade 1 due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy (not including molecularly targeted agents; examples include, but are\r\nnot limited to, tyrosine kinase inhibitors (such as FLT3 inhibitors) and IDH2 inhibitors), radiation treatment and/or surgery 2 weeks prior to entering the study. Those who have not recovered sufficiently from adverse events due to agents administered more than 2 weeks earlier are also ineligibleXx_NEWLINE_xXPatient has received chemotherapy or radiotherapy within 4 weeks prior to entering the study or has not recovered sufficiently (PI will judge patient recovery status) from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of study drug administration or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXSubjects who have received investigational agents, cytotoxic chemotherapy, or radiotherapy within 28 days prior to entering the study, or who have not recovered from AEs dur to agents administered more than 28 days earlier.Xx_NEWLINE_xXPatients who have had chemotherapy/radiotherapy and/or targeted agents within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; the washout chemotherapy/radiotherapy and/or target agents for these patients will be at the investigator’s discretion.Xx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered (Common Terminology Criteria for Adverse Events [CTCAE] v4.03 grade =< 1) from adverse events due to agents administered more than 3 weeks earlier, unless those events are deemed to have returned to baseline, are\r\nirreversible, or are unlikely to develop into a life-threatening condition at the permission of the protocol chair (e.g., alopecia); hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registrationXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy prior to entering the study must have recovered from adverse events to grade 1Xx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to starting study treatment or those who have not recovered from adverse events due to agents administered more than 3 weeks earlierXx_NEWLINE_xXParticipants who have had radiotherapy or chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlierXx_NEWLINE_xXPatients who are receiving any concurrent investigational agent with known or suspected activity against multiple myeloma, or those whose adverse events due to agents administered more than 4 weeks earlier have not recovered to a severity of grade 0 or grade 1Xx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had immunotherapy or radiotherapy within 4 weeks prior to study treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to study treatment; prior history of palliative radiation for symptomatic bony or brain metastases is permissibleXx_NEWLINE_xXPatients who have received chemotherapy or radiotherapy within 2 weeks prior to entering the study or has not recovered from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosourea or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events (less than or equal to grade 1 toxicity) due to agents administered more than 4 weeks earlierXx_NEWLINE_xXRadiotherapy within 2 weeks prior to taking the first dose of study drug, or those who have not recovered from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients may have had one or more prior therapies; prior therapy should have completed within 3 weeks (6 weeks for nitrosoureas or mitomycin C, 5 half-lives for targeted therapies) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier; concurrent palliative radiotherapy is allowed at the discretion of the treating physicianXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C, 5 half-lives for targeted therapies) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier; concurrent palliative radiotherapy is allowed at the discretion of the treating physicianXx_NEWLINE_xXSubjects who have had immunotherapy, chemotherapy, or radiation therapy within 14 days (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have not recovered to grade 1 or less from any adverse events due to agents administered more than 4 weeks earlier (excluding alopecia)Xx_NEWLINE_xXParticipants who have had anti-tumor therapy or other investigational agents within 4 weeks prior to registration (6 weeks for nitrosoureas or mitomycin C), or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to registrationXx_NEWLINE_xXPatients who have received itraconazole or fluconazole within 3 weeks prior to registration or those who have not recovered (i.e., back to baseline or grade 1) from adverse events (AEs) due to agents administered more than 3 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients who have had targeted therapy will be required to wait 2 weeks due to short half-life of the drugs; treatment with bisphosphonates is permittedXx_NEWLINE_xXPatients who have had chemotherapy or RT within 3 weeks prior to start of the study agents, or those who have not recovered from adverse events due to agents administered more than 3 weeks earlierXx_NEWLINE_xXPatients must not have received prior chemotherapy or radiation for =< 3 weeks before study enrollment, or those who have not recovered from the adverse events due to agents administered more than 3 weeks earlier are excludedXx_NEWLINE_xXPrior chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients have received prior chemotherapy or radiation for AML < two weeks before study enrollment, or those who have not recovered from the adverse events due to agents administeredXx_NEWLINE_xXPatients must not have received prior chemotherapy (pentostatin) within 4 weeks before study enrollment, and those who have not recovered from the adverse events due to agents administered more than 4 weeks earlier are excludedXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than 4 weeks earlierXx_NEWLINE_xXChemotherapy or radiotherapy within 4 weeks (or targeted therapies 5 half-lives) prior to entering the study, or failure to recover from adverse events due to agents administered to =< grade 1 or stable grade 2, at the discretion of the treating physicianXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatient has received chemotherapy or radiotherapy within 2 weeks prior to entering the study or has not recovered from adverse events due to agents administered more than 2 weeks earlier, with the exception of hydroxyureaXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had cytotoxic anticancer chemotherapy or immune checkpoint inhibitor within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or palliative radiation within 2 weeks (stereotactic radiation therapy [SRS] for brain metastasis within 48 hours) prior to entering the study or those who have not recovered from adverse events (>= grade 2) due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have not recovered to =< grade 1 from adverse events due to agents administered >= 28 days prior to registration are not eligibleXx_NEWLINE_xXPrevious cytotoxic chemotherapy must have been completed at least 3 weeks and radiotherapy at least 2 weeks prior to day 1 of treatment on the study, and all adverse events (excluding alopecia) due to agents administered more than 4 weeks earlier should have recovered to < grade 1; participants with hematologic malignancies are expected to have hematologic abnormalities at study entry; hematologic abnormalities that are thought to be primarily related to leukemia are not considered to be toxicities (adverse events [AE]) and do not need to resolve to < grade 1Xx_NEWLINE_xXPatients who have had chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy within 2 weeks for antecedent malignancies prior to entering the study, or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior Therapy\r\n* Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier\r\n* Systemic steroids that have not been stabilized (>= 5 days) to the equivalent of =< 10 mg/day prednisone prior to the start of the study drugs\r\n* No other concurrent investigational agents are allowedXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy within 3 weeks, rituximab or obinutuzumab within 4 weeks, or radioimmunotherapy within 6 weeks prior to entering the study, or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier; subjects actively progressing within that window who have recovered from toxicities of prior therapy are also eligibleXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier (e.g. alopecia, hypothyroid, neuropathy, etc.)Xx_NEWLINE_xXPatients must not have received prior chemotherapy or radiation for =< 3 weeks before study enrollment, or those who have not recovered from the adverse events due to agents administered more than 3 weeks earlier are excludedXx_NEWLINE_xXSubjects who have had standard cytotoxic chemotherapy or radiotherapy within 4 weeks prior to entering the study or those whose adverse events due to agents administered more than 4 weeks earlier have not recovered to =< grade 1; this excludes alopecia and hematologic adverse eventsXx_NEWLINE_xXSubjects who have received monoclonal antibodies (such as Rituxan) within 1 week prior to entering the study or those whose adverse events due to agents administered more than 1 week earlier have not recovered to =< grade 1; this excludes hematologic adverse eventsXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXHave not recovered from adverse events (must be grade ?1) due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXPatients who have had chemotherapy, hormonal therapy, or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier; concomitant treatment with bone-targeted therapies such as receptor activator of nuclear kappa-B ligand (RANKL) inhibitors or bisphosphonates is allowedXx_NEWLINE_xXPatients who have had chemotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; recovery means resolution to at least grade 1 toxicity if there was no baseline toxicity or less than or equal to the patient’s baseline valueXx_NEWLINE_xXJUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS): patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered to baseline from adverse events due to agents administered more than 2 weeks earlier (washout period)Xx_NEWLINE_xXPatient who has had chemotherapy or exposure to a CDK 4/6 inhibitor within 3 weeks (6 weeks for nitrosoureas, mitomycin C or bevacizumab) who has not recovered from the adverse events due to previous agents administered more than 4 weeks prior to study day 1; hormonal therapy must be discontinued at least 24 hours prior to starting study treatmentXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of starting treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients may not have had hormonal therapy within 2 weeks prior to entering the study; patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactionsXx_NEWLINE_xXExperiencing adverse events due to agents administered more than 30 days earlierXx_NEWLINE_xXPatients who have previously received chemotherapy for non-small cell lung cancer, or have received radiotherapy within 2 weeks prior to entering the study, or who have not recovered from adverse events due to treatment more than 2 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C, or monoclonal antibodies such as bevacizumab, cetuximab or panitumumab) prior to entering the study or those who have not recovered to =< grade 2 adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered to =< grade 1 adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have not recovered from adverse events due to therapeutic interventions administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had treatment with chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to starting study treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy within 4 weeks prior to entering the study, or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier are excluded; this does not include the use of steroids which may continue until two days prior to enrollmentXx_NEWLINE_xXParticipants who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study entry or those with adverse events due to agents administered more than 4 weeks earlier that have not resolved to =< grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4Xx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; participants who have been treated with a tyrosine kinase inhibitor within 14 daysXx_NEWLINE_xXPreviously treated with irinotecan, or had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study, or not recovered from adverse effects due to agents administered more than 4 weeks earlierXx_NEWLINE_xXReceiving MDS treatment except blood transfusion and/or iron chelation within 4 weeks prior to entering study or no recovery from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXPatients who have not recovered to grade 1 or less from any adverse events due to agents administered more than 4 weeks earlier (excluding alopecia)Xx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; biological agents, immune modulators, and targeted therapeutic approaches require a 2-week washout windowXx_NEWLINE_xXPrior chemotherapy, biologic, targeted, or radiotherapy within 3 weeks prior to entering study or not recovered from grade >= 2 adverse events (AEs) due to agents administered more than 4 weeks earlier (except alopecia or neuropathy)Xx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study enrollment or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to study enrollmentXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier; patients may have received dexamethasone within 2 weeks prior to entering studyXx_NEWLINE_xXPatients who have had chemotherapy (including investigational cytotoxic chemotherapy), biologic agents (e.g., cytokines or antibodies) or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) before the first dose of study treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients must have discontinued chemotherapy, immunotherapy or other investigational agents used in the adjuvant setting >= 4 weeks prior to randomization and recovered from adverse events due to those agents; mitomycin and nitrosoureas must have been discontinued at least 6 weeks prior to entering the study; patients must have discontinued radiation therapy >= 2 weeks prior to entering the study and recovered from any adverse events associated with treatment; prior surgery must be >= 4 weeks from randomization and patients must be fully recovered from post-surgical complicationsXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy including complementary and alternative medicine treatments (CAMs) within 4 weeks prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy 4 weeks or more prior to entering the study who’s adverse events have not recovered to grade 1 or less with the exception of alopecia and neuropathyXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those whose adverse event due to agents administered more than 4 weeks earlier have not resolved or stabilized; patients who have been administered ABT-888 as part of a single or combination, phase 0 or I study, should not necessarily be excluded from participating in this study solely because of receiving prior ABT-888Xx_NEWLINE_xXPatients who have had systemic (IV) cytotoxic chemotherapy or any other investigational agents within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; if a patient received an oral agent, treatment on study cannot commence at least five half-lives of the agent have elapsedXx_NEWLINE_xXDOSE ESCALATION COHORT: Patient has received chemotherapy within 3 weeks prior to entering the study or has not recovered sufficiently (i.e., greater than grade 1; PI will judge patient recovery status) from adverse events due to agents administered more than 3 weeks earlier; exceptions are stable chronic toxicities not expected to resolve, such as peripheral neurotoxicity, alopecia, and fatigueXx_NEWLINE_xXDOSE EXPANSION COHORT: Patient has received chemotherapy within 3 weeks prior to entering the study or has not recovered sufficiently (i.e., greater than grade 1, PI will judge patient recovery status) from adverse events due to agents administered more than 3 weeks earlier; exceptions are stable chronic toxicities not expected to resolve, such as peripheral neurotoxicity, alopecia, and fatigueXx_NEWLINE_xXParticipants who have had chemotherapy, targeted small molecule therapy, or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; in addition, no small molecule kinase inhibitors or any other type of investigational agent may have been administered within 4 weeks before first dose of study treatmentXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier, excluding alopecia; patients with treatment related effects, such as peripheral neuropathy, that are grade 1 or less are eligibleXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of starting treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients may not have had hormonal therapy within 2 weeks prior to entering the study; patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactionsXx_NEWLINE_xXPatients who have had chemotherapy, targeted small molecule therapy, or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\r\n* Note: patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 3 weeks (8 weeks for radioimmunotherapy) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlierXx_NEWLINE_xXPatients must have recovered to at least eligibility levels due to adverse events (AEs) and/or toxicity of prior chemotherapy or biologic therapy; they must not have had chemotherapy or biologic therapy within 4 weeks (6 weeks for nitrosoureas and mitomycin C, or 2 months for UCN-01), or therapy with tyrosine kinase inhibitors within 5 times the half-life of the inhibitors prior to entering the study; patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (also referred to as an “early phase I study” or “pre-phase I study” where a sub-therapeutic dose of drug is administered) at the principal investigator's (PI) discretion, and should have recovered to eligibility levels from any toxicitiesXx_NEWLINE_xXChemotherapy, radiotherapy or hormonal therapy within 3 weeks (6 weeks for nitrosoureas, mitomycin C or bevacizumab), or who have not recovered from the adverse events to < grade 2 due to previous agents administered more than 4 weeks prior to study day 1Xx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier (persistent toxicity >= grade 1)Xx_NEWLINE_xXPatients who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 21 days (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy within 1 week (6 weeks for nitrosoureas or mitomycin C) or investigational therapies/monoclonal antibodies within 5 half-life of investigational compound or those who have adverse events which are greater than grade 1 and are due to agents administered more than 1 week earlier; bisphosphonates, endocrine therapy, and trastuzumab are permitted without restrictionXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 3 weeks, or topical therapy within 2 weeks prior to initiating protocol therapy or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier; patients are allowed to take weak potency topical corticosteroids if patient has been on a stable dose for more than a monthXx_NEWLINE_xXPatients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; there will be at least a 3 week delay from the time of a previous bladder biopsy/transurethral resection of bladder tumor (TURBT) to allow for adequate bladder healing prior to enrollmentXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients who have had prior treatment with any PARP inhibitors are ineligibleXx_NEWLINE_xXPatients who have had cytotoxic chemotherapy, radiotherapy, interferon (IFN), immunosuppressive therapy, or steroids within 4 weeks (6 weeks for nitrosoureas or mitomycin C) before entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy, radiation therapy, or other investigational agents within 3 weeks prior to entering study, 6 weeks for nitrosoureas or mitomycinXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study; hydroxyurea may be administered for count control both pre-treatment and during cycle 1 onlyXx_NEWLINE_xXPatients must have discontinued cytotoxic therapy agents at least 4 weeks, cytokine based immunotherapy at least 6 weeks and immunoregulatory antibody therapy at least 12 weeks prior to entering the study and have recovered from adverse events due to those agentsXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier (with the exception of alopecia and neuropathy); no radiation is allowed on studyXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXChemotherapy (other than hydroxyurea) or radiation within the 2 weeks prior to planned therapy on this study or ongoing adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have radiotherapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to systemic agents administered more than 3 weeks earlierXx_NEWLINE_xXFor patients who have received gamma knife or stereotactic radiosurgery, a 2 week washout is required; patients who have had other types of radiotherapy, chemotherapy or biologic agents within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier to =< grade 1; at least 4 weeks must have elapsed since any major surgery; patients with prostate cancer may continue to receive hormonal therapyXx_NEWLINE_xXPrior systemic chemotherapy for anaplastic thyroid cancer\r\n* Patients who have had chemotherapy or radiotherapy within 4 weeks of registration (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered > 4 weeks previously\r\n* Patients receiving other investigational agentsXx_NEWLINE_xXPatient who has had chemotherapy, radiotherapy, or biological therapy, within 30 days (42 days for nitrosoureas or mitomycin C) or who has not recovered from adverse events due to agents administered more than 30 days earlierXx_NEWLINE_xXPatients who have received systemic cytotoxic chemotherapy, immunotherapy for 3 weeks before initiation of planned WBRT or patients who have not recovered from serious (Common Terminology Criteria for Adverse Events [CTCAE] grade 3 or more) adverse events from the previously received agents; for oral targeted agents or any other investigational agents, at least 4 half-lives of the agent (6 weeks for nitrosoureas or mitomycin C) should have elapsed prior to starting study treatmentXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXNot recovered from adverse events due to therapy more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered > 3 weeks prior to entering the studyXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients who have been administered ABT-888 as part of a single or limited dosing study, such as a phase 0 study, should not necessarily be excluded from participating in this study solely because of receiving prior ABT-888Xx_NEWLINE_xXPatients who have had surgery, chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have toxicity that has not recovered to =< grade 1 from adverse events due to agents administered more than 4 weeks earlier (with the exception of alopecia); patients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events to =< grade 1 due to agents administered more than 4 weeks earlier; for investigational targeted therapies patients will need to clear for 5 half lives (not applicable to standard of care therapies)Xx_NEWLINE_xXPatients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of study drug administration or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have not recovered from adverse events due to agents administered more than 3 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the studyXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C, 3 weeks for rituximab) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXChemotherapy within 4 weeks prior to entering the study, radiotherapy within 2 weeks prior to entering the study or failure to recover from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXReceipt of chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier; however, the following therapies are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1)Xx_NEWLINE_xXSubjects who have had chemotherapy or radiotherapy or any systemic therapy for melanoma within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier; no concomitant therapy is allowed including IL2, interferon, ipilimumab, anti-PD-1 or anti-PD-L1 antibody, cytotoxic chemotherapy, immunosuppressive agents, or other investigational therapiesXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXPatients who have not recovered to =< grade 1 from adverse events due to agents administered more than 4 weeks earlier are not eligibleXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXChemotherapy, within 4 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin) or those who have not recovered to less than or equal to grade 1 from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy, immunotherapy, radiotherapy, or investigational therapy within 28 days prior to entering the study or those who have not recovered from adverse events due to agents administered more than 28 days earlier; steroids for control of disease related symptoms are permittedXx_NEWLINE_xXChemotherapy within 4 weeks prior to entering the study, radiotherapy within 2 weeks prior to entering the study or failure to recover from adverse events to grade 1 or less due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants may not have had chemotherapy or radiation therapy (RT) within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study and must have recovered to =< grade 1 from adverse events due to agents administered more than 3 weeks earlier; patients should not have received hormonal therapy for treatment of their cancer within 2 weeks of study entryXx_NEWLINE_xXAny of the following:\r\n* Chemotherapy =< 4 weeks prior to registration \r\n* Radiotherapy =< 4 weeks prior to registration\r\n* Nitrosoureas =< 6 weeks prior to registration or\r\n* Mitomycin C =< 6 weeks prior to registration\r\n* Those who have not recovered from adverse events (to grade =< 1 in severity) due to agents administered more than 4 weeks earlier; prior palliative radiotherapy to bone metastases =< 2 weeks prior to registration (i.e. prior palliative radiotherapy to bone metastases is allowed if it is performed > 2 weeks prior to registration)Xx_NEWLINE_xXPatients who have had targeted therapy, chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than 4 weeks earlier (i.e., grade >= 2 AE present); palliative (limited-field) radiation therapy is permitted, as long as the lesion being considered for palliative radiation is not a target lesionXx_NEWLINE_xXPatients receiving chemotherapy or radiotherapy within 4 weeks of injection of HF10, or history of Grade 4 adverse events or presence of adverse events Grade 2 or greater, except alopecia, resulting from anticancer agents administered more than 4 weeks prior to HF10 injection.Xx_NEWLINE_xXNot recovered from adverse events due to therapy more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy for the treatment of the advanced or unresectable urothelial cancer of the bladder are not eligible; patients who were previously treated for local disease must not have received radiotherapy or chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study and must have recovered from adverse events due to agents administered more than 4 weeks earlier; patients who have received neoadjuvant or adjuvant chemotherapy must have completed treatment at least 6 months prior to diagnosis of metastatic diseaseXx_NEWLINE_xXPatients who have had chemotherapy, radiotherapy, experimental therapy or major surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered (to grade =< 1 or baseline) from clinically significant adverse events due to agents administered more than 4 weeks earlier (alopecia and fatigue excluded); clinical significance to be determined by investigatorXx_NEWLINE_xXParticipants who have had any prior systemic therapy for CLL, or chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) for some other indication prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the studyXx_NEWLINE_xXHas received treatment with radiation therapy, surgery, chemotherapy, or an investigational agent within 4 weeks prior to registration, (6 weeks for radiation therapy, radionuclides, nitrosoureas, or mitomycin C) or who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatient received chemotherapy or radiotherapy within 2 weeks prior to entering the study or has not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlierXx_NEWLINE_xXPrior therapy\r\n* Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier\r\n* Systemic steroids that have not been stabilized (>= 5 days) to the equivalent of =< 10 mg/day prednisone prior to the start of the study drugs\r\n* No other concurrent investigational agents are allowedXx_NEWLINE_xXParticipants who have had chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) or radiation therapy within 2 weeks prior to entering the study or those who have not recovered to =< grade 1 (except alopecia) from adverse events (as per the revised NCI CTCAE version 4) due to agents administered more than 3 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; steroids used for disease related symptoms should be stopped within 48 hours of protocol therapy; patients who have had prior exposure to a Bruton’s tyrosine kinase (BTK) inhibitor; patients who received monoclonal antibody =< 6 weeks prior to first administration of study treatmentXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 14 days prior to entering the study (with the exception of trastuzumab) or those who have not recovered from adverse events to =< grade 1 due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPrior chemotherapy or targeted therapy (including any investigational agents) within 2 weeks prior entering the study or those who have not recovered adequately from adverse events (AEs) due to agents administered more than 4 weeks earlier (excluding alopecia and hot flashes); a washout period is not necessary for trastuzumab or pertuzumab, hormone therapy, or radiation therapyXx_NEWLINE_xXParticipants who have had chemotherapy within 4 weeks prior to entering the study, or lack of recovery from adverse events to grade 1 or less due to systemic agents administered more than 4 weeks earlier; patients can be eligible if 2 weeks have passed since receipt of erlotinibXx_NEWLINE_xXReceipt of radiation therapy within 2 weeks prior to entering the study, or lack of recovery from adverse events to grade 1 or less due to radiation administered more than 2 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXPatients who have had chemotherapy for the treatment of metastatic breast cancer are not eligible. Patients who have had radiotherapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier are not eligible.Xx_NEWLINE_xXPatients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; prior radiation treatment to the target vestibular schwannoma is allowed if provided 3 years prior to participation in the clinical trial; prior radiation treatment to non-target tumors is allowedXx_NEWLINE_xXParticipants who have not recovered from adverse events due to systemic agents administered more than 4 weeks earlier, as determined by the treating physicianXx_NEWLINE_xXParticipants who have had immunotherapy, chemotherapy, experimental therapy or radiotherapy within 4 weeks before first day of study drug dosing or those who have not recovered to grade 1 or baseline from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had myeloma therapy within 14 days prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier; patients may have received bisphosphonate therapy or radiation therapy as part of routine myeloma care at any time prior to study entryXx_NEWLINE_xXPatient has had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas, anti-angiogenic agents, or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had anti-VEGFR tyrosine kinase inhibitor within 1 week, mTOR inhibitor within 1 week or anti-VEGF antibody therapy within 3 weeks prior to entering the study; patients who have had other forms of chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXChemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to day 1 or those who have not recovered from adverse events (AEs) due to agents administered more than 3 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXUse of any other chemotherapy, radiotherapy, or experimental drug or therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to enrollment on study or those who have not recovered from adverse events =< grade 1 due to agents administered more than 4 weeks earlier except for stable grade 2 neuropathyXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy (including investigational agents) within 2 weeks prior to entering the study or those who have not recovered adequately from adverse events due to agents administered more than 4 weeks earlier (excluding alopecia); washout from trastuzumab is not requiredXx_NEWLINE_xXPatient who has had chemotherapy, radiotherapy, or hormonal therapy within 3 weeks (6 weeks for nitrosoureas, mitomycin C or bevacizumab), or who has not recovered from the adverse events due to previous agents administered more than 4 weeks prior to Study Day 1; if the patient has residual toxicity from prior treatment, toxicity must be =< Grade 1Xx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; current treatment with leuprolide or other gonadotropin-releasing hormone (GnRH) agonists is permitted on the Phase I portion of the studyXx_NEWLINE_xXEXPANSION COHORT ONLY: Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatient has had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy =< 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration or those who have not recovered from adverse events due to agents administered >= 4 weeks earlier; patients may not be receiving any other investigational agentsXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlierXx_NEWLINE_xXPatients who, at the discretion of the treating physician, have not recovered from adverse events due to agents administered earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who receive other chemotherapy; patients must have been off previous therapy for >= 2 weeks and must have recovered from clinically significant toxicity (to grade 1 or less) of all previous therapy prior to enrollment (consent signing) with the following exceptions: steroids, hydroxyurea, oral mercaptopurine, methotrexate, vincristine (including prophylactic intrathecal medication), thioguanine, and tyrosine kinase inhibitors are permitted within 2 weeks of randomization as maintenance or to reduce the peripheral blood blast counts; during ibrutinib therapy, only steroids and hydroxyurea are permitted to reduce peripheral blood blast counts; patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy (including targeted therapy i.e. cetuximab, panitumumab) or radiotherapy =< 4 weeks or treatment with bevacizumab =< 6 weeks prior to entering the study or those who have not recovered from acute adverse events due to agents administered more than 4 weeks earlier, with the exclusion of alopecia or neuropathy; patients with history of radiation to the liver including radio-labeled microspheres at any point in their past will be excludedXx_NEWLINE_xXPatients who have had radiotherapy within 6 months prior to entering the study or those who have not recovered to < grade 2 adverse events due to radiationXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 6 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 6 weeks earlier.Xx_NEWLINE_xXPatients who have had chemotherapy, immunotherapy, or investigational anti-cancer therapy within 4 weeks of starting study drug, or radiotherapy within 14 days of starting study drug, or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients receiving immunotherapy, hormonal-therapy and or radiotherapy within 2 weeks prior to entering the study; Note: those who have not recovered from adverse events due to these agents administered will be considered ineligibleXx_NEWLINE_xXPatients who have had major surgery, chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlierXx_NEWLINE_xXParticipants who have had anti-neoplastic treatment for KS (including chemotherapy, radiotherapy, local treatment including topical fluorouracil [5-FU], biological therapy or investigational therapy) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study OR those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events (CTCAE v4.03 grade 2 or greater, excluding alopecia) due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 3 weeks (4 weeks for radiotherapy to the lung fields and 6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study; patients who have had prior onalespib or AT7519M as a monotherapy will not be excludedXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events from prior treatmentsXx_NEWLINE_xXPatients should not have received any chemotherapy or investigational agents for at least 4 weeks before entering the study (6 weeks for nitrosoureas or mitomycin C)Xx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered to =< grade 1 (or =< tolerable grade 2 for neuropathy) adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had systemic therapy for melanoma or radiotherapy within 3 weeks prior to registering on the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier; patients with a history of endocrinopathies (e.g. hypothyroidism, adrenal insufficiency, hypopituitarism) are eligible if they are stable on hormone replacement therapyXx_NEWLINE_xXPatients who have had palliative chemotherapy prior to entering the study < 12 months from enrollment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the studyXx_NEWLINE_xXPatients who have had chemotherapy or targeted small molecule therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\r\n* Note: patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy =< 21 days (=< 6 weeks for monoclonal antibodies) prior to first administration of study treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy, biologic, targeted, or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from grade 2 and above adverse events due to agents administered more than 4 weeks earlier (with the exception of alopecia or neuropathy)Xx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse event from agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier to grade 1 or below (unless approved by the study chair)Xx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXSubject who has had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from prior treatment related toxicity with persistent symptoms >/= grade 2 due to agents administered more than 4 weeks earlier.Xx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C), or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (CTCAE Grade > 1) due to agents administered more than 3 weeks earlier.Xx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 30 days (6 weeks for nitrosoureas or mitomycin C) prior to study screening or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy (non-tyrosine kinase inhibitor [TKI]) or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXAny of the following:\r\n* Chemotherapy =< 3 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin C)\r\n* Radiotherapy, endocrine therapy or targeted therapy for malignancy =< 2 weeks prior to registration\r\n* Patients who have not recovered (=< grade 1) from adverse events due to agents administered more than 4 weeks earlier (tolerable grade 2 adverse events may be allowed at the discretion of the investigator; diarrhea must be grade 1 or lower without the scheduled use of antidiarrheal medications)\r\n* Prior anticancer therapy with an mammalian target of rapamycin (mTOR) inhibitor (everolimus, temsirolimus, desferolimus) or agent specifically targeting c-MetXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXChemotherapy, radiotherapy, or surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have not recovered from adverse events due to prior agents; a minimum interval of 3 weeks should have elapsed from prior radiotherapy and/or chemotherapyXx_NEWLINE_xXPatients must not have received systemic therapy or radiotherapy within the preceding 4 weeks; patients must have recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (toxicities not improved to =< grade 1) due to agents administered more than 4 weeks earlier; additionally, patients experiencing disease progression within 3 months of platinum-based therapy will be excluded from trial participationXx_NEWLINE_xXThe participant has not recovered to Grade ? 1 from adverse events due to agents administered more than 4 weeks prior to study entry (except for alopecia)Xx_NEWLINE_xXPatients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the studyXx_NEWLINE_xXPatients who have had chemotherapy, immunotherapy, or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events (=< grade 1 or patient’s baseline) due to agents administered more than 2 weeks earlier are not eligibleXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy or targeted agents within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had chemotherapy or extra-cranial radiotherapy within 4 weeks prior to study screening or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to the completion of study screeningXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier will be excludedXx_NEWLINE_xXSubjects who have had radiotherapy within 12 weeks prior to entering the study or those who have not recovered from adverse events due to agents or therapies administered for treatment of prostate cancer more than 4 weeks earlier- (except urinary, rectal, and sexual side effects related to prostatectomy or radiotherapy are permitted)Xx_NEWLINE_xXPatients who are:\r\n* Receiving or received treatment with an investigational agent within 4 weeks prior to entering the study OR\r\n* Have not recovered from adverse events due to agents administered more than 4 weeks earlier as determined by the treating physicianXx_NEWLINE_xXPatients who have had chemotherapy or targeted small molecule therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) before entering the studyXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXPatients who have had other chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier are not eligible.Xx_NEWLINE_xXPatients who have had antifungal agents (itraconazole, fluconazole) within 4 weeks prior to treatment start or those who have not recovered from adverse events (AEs) due to these agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXParticipants who have had chemotherapy, radiotherapy, biological therapy, immunotherapy or other anticancer agents within 14 days (six weeks for nitrosoureas or mitomycin C) prior to entering the studyXx_NEWLINE_xXPatients who have had chemotherapy or immunotherapy within 4 weeks of starting study drug, or radiotherapy within 14 days of starting study drug, or those who have not recovered from adverse events due to agents administered more than 4 weeks earlierXx_NEWLINE_xXSubjects who have not recovered from adverse events due to pharmaceutical or diagnostic agents administered more than 4 weeks earlier.Xx_NEWLINE_xXSubjects who have not recovered from adverse events due to pharmaceutical or diagnostic agents administered more than 4 weeks earlier.Xx_NEWLINE_xX